LivaNova (LIVN) Expected to Announce Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is expected to be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect LivaNova to announce earnings of $1.06 per share and revenue of $381.10 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.17. The business had revenue of $390.59 million during the quarter, compared to the consensus estimate of $380.50 million. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.05 EPS. On average, analysts expect LivaNova to post $3.78 EPS for the current fiscal year and $4.16 EPS for the next fiscal year.

LivaNova Stock Performance

NASDAQ LIVN opened at $80.38 on Wednesday. LivaNova has a twelve month low of $48.82 and a twelve month high of $85.76. The stock has a fifty day simple moving average of $78.45 and a 200 day simple moving average of $72.66.

Analyst Ratings Changes

LIVN has been the topic of several recent research reports. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 target price (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd. Barclays raised LivaNova to a “strong-buy” rating in a research note on Wednesday, October 7th. Stifel Nicolaus set a $85.00 price objective on LivaNova in a research report on Wednesday, August 5th. Zacks Research lowered LivaNova from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Finally, Mizuho lifted their price objective on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $87.75.

Insiders Place Their Bets

In other LivaNova news, Director Brooke Story sold 2,300 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $81.42, for a total transaction of $187,266.00. Following the sale, the director owned 7,488 shares of the company’s stock, valued at approximately $609,672.96. This represents a 23.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Francesco Bianchi sold 3,500 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the sale, the director directly owned 4,434 shares in the company, valued at $345,896.34. This trade represents a 44.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 7,450 shares of company stock valued at $591,839 in the last three months. 0.35% of the stock is owned by insiders.

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.